Draft Guidance on Phenytoin Sodium

Active Ingredient: Phenytoin sodium

Dosage Form; Route: Extended release capsule; oral

Recommended Studies: Two studies

1. Type of study: Fasting
Design: Single-dose, 2-treatment, 2-sequence, 4-period, fully replicated crossover in vivo
Strength: 300mg (dose: 1 X 300mg)
Subjects: Normal healthy males and females, general population
Additional comments: Washout period of at least 14 days. The strength(s) designated in the Orange Book as the reference listed drug (RLD) should be used in the studies. The applicant should use the reference-scaled average bioequivalence approach for phenytoin sodium.

2. Type of study: Fed
Design: Single-dose, 2-treatment, 2-sequence, 4-period, fully replicated crossover in vivo
Strength: 300mg (dose: 1 X 300mg)
Subjects: Normal healthy males and females, general population
Additional comments: See comments above

Analytes to measure: Phenytoin in plasma

Bioequivalence based on (90% CI): Phenytoin

Waiver request of in vivo testing: 200mg based on (i) acceptable bioequivalence studies on the 300mg strength, (ii) proportionally similar across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Conduct comparative dissolution testing on 12 dosage units of all strengths of the test and reference products using the USP method.

In addition to the method above, dissolution profiles on 12 dosage units each of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5, and 6.8 buffer) should be submitted in the

Recommended May 2007; Revised Dec 2014
application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation. Specifications will be determined upon review of the data submitted in the application.

**Explanation:** FDA has concluded that phenytoin is a narrow therapeutic index (NTI) drug based on the following evidence:

- The range between the effective phenytoin concentrations and the concentrations associated with serious toxicity is narrow
- Sub-optimal doses or concentrations lead to therapeutic failure or severe toxicity
- Phenytoin is subject to therapeutic monitoring based on pharmacokinetics measures
- Phenytoin has low-to-moderate within-subject variability
- Doses are adjusted in small increments (less than 20%) in clinical practice

The study should be a fully replicated crossover design in order to:

- Scale bioequivalence limits to the variability of the reference product
- Compare test and reference product within-subject variability

For details about the Method for Statistical Analysis Using the Reference-Scaled Average Bioequivalence Approach for NTI drugs, refer to *Draft Guidance on Warfarin Sodium.*